| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Molecular Biology, Pathobiology, and Genetics |
Departments of 1 Anatomy and Cell Biology and 2 Biochemistry and Molecular Biology, 3 Program in Cancer Genetics, Epigenetics and Tumor Virology, and 4 Program in Signaling, Apoptosis and Cancer, Shands Cancer Center, University of Florida College of Medicine, Gainesville, Florida
Requests for reprints: Daiqing Liao, Department of Anatomy and Cell Biology, Shands Cancer Center, University of Florida College of Medicine, P.O. Box 103633, 1376 Mowry Road, Gainesville, FL 32611-3633. Phone: 352-273-8188; Fax: 352-273-8285; E-mail: dliao{at}ufl.edu.
In a genome-wide screen for putative tumor suppressor genes, the EBF3 locus on the human chromosome 10q26.3 was found to be deleted or methylated in 73% of the examined cases of brain tumors. EBF3 is expressed in normal brain but is silenced in brain tumors. Therefore, it is suggested that EBF3 is a tumor suppressor. However, it remains unknown whether inactivation of EBF3 locus also occurs in other types of tumors and what functions of EBF3 underlie EBF3-mediated tumor suppression. We show here that expression of EBF3 resulted in cell cycle arrest and apoptosis. The expression of cyclin-dependent kinase inhibitors was profoundly affected with early activation and then repression of p21cip1/waf1 and persistent activation of both p27kip1 and p57kip2, whereas genes involved in cell survival and proliferation were suppressed. EBF3 bound directly to p21cip1/waf1 promoter and regulated transcription from both p21cip1/waf1 and p27kip1 promoters in reporter assays. Apoptosis occurred 48 hours after EBF3 expression with caspase-3 activation. Silencing of the EBF3 locus was observed in brain, colorectal, breast, liver, and bone tumor cell lines and its reactivation was achieved on treatment with 5-aza-2'-deoxycytidine and trichostatin A in a significant portion of these tumor cells. Therefore, EBF3 regulates a transcriptional program underlying a putative tumor suppression pathway. (Cancer Res 2006; 66(19): 9445-52)
This article has been cited by other articles:
![]() |
L. Mao, H. Wang, Y. Wang, S. Ju, Y. Wu, and X. Jin Increased Expression of Early B-cell Factor 3 in Human Hepatocellular Carcinoma and the Effect of EBF3 Overexpression on HepG2 Cell Cycling Lab Med, January 1, 2009; 40(1): 39 - 46. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. L. Bennett, M. Karpenko, M.-t. Lin, R. Claus, K. Arab, G. Dyckhoff, P. Plinkert, E. Herpel, D. Smiraglia, and C. Plass Frequently Methylated Tumor Suppressor Genes in Head and Neck Squamous Cell Carcinoma Cancer Res., June 15, 2008; 68(12): 4494 - 4499. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Y. Zhao, A. Santiago, J. Liu, and D. Liao Repression of p53-mediated Transcription by Adenovirus E1B 55-kDa Does Not Require Corepressor mSin3A and Histone Deacetylases J. Biol. Chem., March 9, 2007; 282(10): 7001 - 7010. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |